Actinogen Medical (ACW) Stock Price, News & Analysis

Company Overview

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 275,000 shs
• Average Volume: N/A
• Market Capitalization: A$122.18 million
• P/E Ratio: N/A
• Dividend Yield: 8.76%
• Price Target: N/A
• Consensus Rating: N/A

ACW Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Actinogen Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Actinogen Medical investors own include Vocus Group (VOC), Oncolytics Biotech (ONCY), Chorus (CNU), Biosig Technologies (BSGM) and Admedus (AHZ).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Automobiles And Trucks
• Current Symbol: ASX:ACW
• CIK: N/A
• Web: www.actinogen.com.au
• Phone: 61 2 8964 7401
• Fax: N/A
• Employees: 1,766
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): A($0.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -A$13.04 million
• Net Margins: -131.34%
• Pretax Margin: N/A
• Return on Equity: -82.36%
• Return on Assets: -45.37%

Debt

• Debt-to-Equity Ratio: 1.62
• Current Ratio: 13.91
• Quick Ratio: 13.73

Sales & Book Value

• Annual Sales: A$9.93 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 2.38
• Book Value: A$0.01 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 3,080,000,000
• Free Float: N/A
• Market Cap: A$122.18 million
• Optionable: Not Optionable
• Beta: 1.74